Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MDx Platform Offers Largest Variety of Leukemia-Related Diagnostic Tests for Early Detection

By LabMedica International staff writers
Posted on 26 Apr 2023

Leukemia, also known as blood cancer, is a malignant disease affecting the blood system. More...

It is the most common cancer in children under 15, accounting for roughly one-third of all childhood tumors. The number of leukemia cases is rising annually. Traditional leukemia detection involves blood tests followed by a bone marrow biopsy, which can be time-consuming and subjective due to the reliance on human interpretation of cytology. This process typically takes between 3 to 6 weeks. Now, a new molecular leukemia diagnostic platform offers 12 molecular diagnostic tests specialized in leukemia early diagnosis, treatment guidance and MRD (Minimal residual disease) monitoring.

Alercell, Inc. (Bozeman, MT, USA) has unveiled the LENA Molecular Dx Leukemia Platform, a set of 12 next-generation DNA sequencing tests that can be processed using a standard qPCR machine. The tests have a user-friendly protocol, are compatible with standard qPCR equipment, and are designed to fit into the workflow of a clinical microbiology lab. These tests utilize industry-standard PCR and DNA purification technology.

Some of the tests are designated for Research Use Only (RUO), such as the RUO LENA Q51 introduced by Alercell in January 2023. LENA Q51 is the most comprehensive test, encompassing all other tests, although the company aims to make all tests accessible through the platform. Alercell plans to add new tests to cover all aspects of leukemia testing, providing practitioners with a single location for every available test. By offering these tests at competitive prices, Alercell seeks to increase access for more patients, hospitals, and cancer centers, leading to early detection and prompt treatment of leukemia.

“This new platform was designed to create a one-stop-shop for Leukemia, where practitioners do not need to look for many different manufacturers,” said Frederic Scheer, chairman & CEO of Alercell. “Our goal at Alercell is to become the reference for Leukemia and offer a complete solution. Our R&D team is working on additional tests to add to the platform in the months and years to come. I believe that several of the tests designed to improve patient outcomes will assist practitioners in selecting the appropriate therapeutics for Leukemia patients. Early detection drastically enhances the survival rates of patients and Alercell is focusing on making sure that we give every patient the best chances of survival.”

Related Links:
Alercell, Inc. 


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.